<DOC>
	<DOCNO>NCT00002970</DOCNO>
	<brief_summary>Phase II trial study effectiveness 506U78 treat patient recurrent refractory hematologic cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>506U78 Treating Patients With Refractory Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate compound 506U78 ( 2-amino-9-b-D-arabinofuranosyl-6-methoxy-9H-purine ) administer 1 hour infusion daily 5 day patient recurrent T-cell malignancy . II . Determine toxicities compound 506U78 group patient . III . Correlate biochemical pharmacology compound 506U78 ( e.g. , ara-G nucleotide leukemic blast CSF concentration ) clinical response . IV . Determine impact compound 506U78 therapy survival duration response patient recurrent T-cell malignancy . OUTLINE : Patients stratify accord disease characteristic : Group 1 : T-cell ALL NHL first relapse ( great 25 % bone marrow blast , without concomitant extramedullary relapse CNS ) ; Group 2 : T-cell ALL NHL second later relapse ( great 25 % bone marrow blast , without concomitant extramedullary relapse CNS ) ; Group 3 : T-cell ALL NHL positive bone marrow CSF ( great 5 % bone marrow blast CNS 2 3 involvement ) ; Group 4 : Extramedullary relapse le 25 % blast bone marrow ( exclude isolate CNS relapse ) GROUP 1 : Patients receive 1 hour infusion compound 506U78 daily 5 day absence neurologic toxicity . The course repeat every 21 day . If first relapse T-cell ALL study high priority open , patient may continue receive drug every 21 day maximum 2 year provide patient achieved second complete response . GROUPS 2 4 : Patients receive compound 506U78 every 21 day maximum 2 year , absence disease progression . After 3 course patient may give CNS prophylaxis triple intrathecal therapy ( TIT ) , consist methotrexate , cytarabine hydrocortisone consultation study coordinator . TIT give every 12 week . GROUP 3 : Patients receive compound 506U78 every 21 day maximum 2 year , absence disease progression . TIT give day 1 week 1-4 , 6 , 9 every 6 week 12 week , every 9 week thereafter . This stratum open .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Refractory recurrent acute lymphocytic leukemia ( ALL ) nonHodgkin 's lymphoma ( NHL ) bone marrow involvement ( Tcell disease ) Isolated CNS relapse eligible Performance status Karnofsky 50100 % At least 8 week Bilirubin great 1.5 mg/dL SGPT le 5 time normal Creatinine normal age Creatinine clearance GFR least 60 mL/min/1.73m2 No severe uncontrolled infection No concurrent biologic therapy Recovered toxic effect At least 6 week administration nitrosoureas No concurrent endocrine therapy At least 6 week administration craniospinal hemi pelvic radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>